Pfizer Forecasts 2023 Revenue of $67B–$71B, Down Up to 33% Year-over-Year

Pfizer, Inc. released its 2023 sales guidance on January 31, forecasting 2023 revenue to be between $67 billion and $71 billion, a drop of up to 33% from its record $100.3 billion in 2022, which was driven by over $50 billion in sales of COVID-19 vaccines and antiviral drugs. Pfizer expects 2023 earnings per share to be between $3.25 and $3.45, a decrease of up to 50% from the record $6.58 in 2022.